Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Anti-CXCR4 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm A: Anti-CXCR4 (BMS-936564)+Lenalidomide+Dexamethasone | EXPERIMENTAL | - |
| Arm B: Anti-CXCR4 (BMS-936564)+Bortezomib+Dexamethasone | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Anti-CXCR4 (BMS-936564) | BIOLOGICAL | Solution, Intravenously, 1-10 mg/kg, Single 60 minute infusion once a week, 42 days (cycle 1) 28 days subsequent cycles |
| Lenalidomide | BIOLOGICAL | Tablets, per os (by mouth route of administration) (P.O), 25 mg, daily for 21 days (Day 15-35 in cycle 1; Day 1-21 in subsequent cycles), no dosing in Cycle 1, Cycle 2 +:daily dosing from Day 1-21 |
| Dexamethasone | BIOLOGICAL | Tablets, per os (by mouth route of administration) (P.O), 40 mg, administered with Lenalidomide once every 7 days, 42 days (cycle 1) 28 days subsequent cycles |
| Bortezomib | BIOLOGICAL | Intravenous (IV), 1.3 mg/m2, administered on day 15, 18, 22, 25 in cycle 1, then on Day 1, 4, 8, 11 in subsequent cycles, no dosing in Cycle 1, Cycle 2 +:dosing on Day 1, 4, 8, 11 |
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. Inclusion Criteria: * Subjects must have confirmed diagnosis of multiple myeloma with measurable disease Excluded are subjects with only plasmacytomas, plasma cell leukemia, or non-secretory myel...
Top 20 of 25 competitors
Anti-CXCR4 is an investigational monoclonal antibody being studied for the treatment of multiple myeloma. It is being developed by Bristol-Myers Squibb Company (BMY) and is currently in Phase 1 clinical development. The drug has been evaluated in a completed clinical trial involving patients with relapsed or refractory multiple myeloma.
Anti-CXCR4 targets the CXCR4 receptor, a protein involved in cell signaling that can play a role in cancer progression and metastasis. By binding to CXCR4, the antibody is designed to interfere with this signaling pathway. This mechanism is being explored as a potential therapeutic approach in multiple myeloma.
Anti-CXCR4 is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol BMY. The drug is an investigational monoclonal antibody currently in Phase 1 clinical development for the treatment of multiple myeloma.
Anti-CXCR4 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 clinical trial of the drug has been completed, evaluating its safety and efficacy in patients with relapsed or refractory multiple myeloma.
Anti-CXCR4 has been studied in one completed clinical trial, identified as NCT01359657. This Phase 1 trial evaluated the drug alone and in combination with lenalidomide/dexamethasone or bortezomib/dexamethasone in patients with relapsed or refractory multiple myeloma. The trial enrolled 46 participants in the United States.
Yes, Anti-CXCR4 is also known as BMS-936564. The clinical trial NCT01359657, which evaluated the drug in multiple myeloma, used the name BMS-936564 in its title. This alternative name may be used in scientific literature and clinical trial registries.